Search Results

CYduct Diagnostics, Inc. (OTC PINK:CYDX) (“CYduct”, “CYductDX”, or the “Company”), an innovator in precision breast health enabled by non-invasive intraductal platforms, today announced it is pleased to present at the 2024 Yale Innovation Summit, being held from May 29-30 in New Haven, CT.

Transcend Therapeutics, a biotechnology company developing rapid-acting treatments for neuropsychiatric diseases, announced receipt of a collaborative grant award with Yale University to support first-of-its-kind preclinical research on methylone – Transcend’s lead compound for the treatment of post-traumatic stress disorder (PTSD).

NexImmune, Inc. announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells.

Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that Christoper van Dyck, M.D., the director of the Yale Alzheimer’s Disease Research Unit and the Yale Alzheimer’s Disease Research Center, is presenting the Phase 2 study design of the company’s ongoing START study in an oral late-breaking session at Clinical Trials on Alzheimer’s Disease (CTAD) conference.

Marking a milestone development in epigenetic research and clinical health applications, laboratory TruDiagnostic is launching the first ever, epigenetic aging analysis of individual organ systems, using validated and system-specific trained clocks.

Trevi Therapeutics, Inc. today announced its participation at the upcoming Yale Innovation Summit taking place from May 31 – June 1 at the Yale School of Management.

Algernon Pharmaceuticals Inc. is pleased to announce that it has entered an Investigator-Initiated Clinical Trial Agreement (“CTA”) with Yale University (“Yale”) for the investigation of multiple intravenous doses of DMT for the treatment of depression.

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

Biohaven Ltd. announced advancements in the development of its MoDE extracellular target degrader platform technology licensed from Yale University for various disease indications, including, but not limited to, neurological disorders, cancer, infectious and autoimmune diseases.